Phase 1 Open-Label Study With A Novel Triple Mechanism Of Action IP In Combination With Pembrolizumab For Advanced Malignancies. Read more
A Phase 1/2, Open-Label Study Investigating The Safety, Tolerability And Efficacy Of ASP7517 As A Single Agent And In Combination With Pembrolizumab In Patients With Advanced Solid Tumors Known To Express WT1 Antigen Read more
A Phase 2 Study Of Dabrafenib (NSC# 763760) With Trametinib (NSC# 763093) After Local Irradiation In Actively-Diagnosed BRAF V600-Mutant High-Grade Glioma (HGG) Read more
A Phase 2 Study Of Veliparib (ABT-888) And Local Irradiation, Followed By Maintenance Veliparib And Temozolomide, In Patients With Actively Diagnosed High-Grade Glioma (HGG) Without H3 K27M Or BRAFV600 Mutations Read more
A Phase 3 Randomized Non-Inferiority Study Of Carboplatin And Vincristine Versus Selumetinib (NSC# 748727) In Actively Diagnosed Or Previously Untreated Low-Grade Glioma (LGG) Not Associated With BRAFV600E Mutations Or Systemic Neurofibromatosis Type 1 (NF1) Read more
A Phase 1/1b, Open-Label Multi-Center Two Part Study Of Setd2 Inhibitor Ezm0414 In Subjects With Relapsed/Refractory Multiple Myeloma And Relapsed/Refractory Diffuse Large B Cell Lymphoma Read more
A Phase 2 study of Paxalisib (GDC-0084) in recurrent or refractory Primary Central Nervous System Lymphoma (PCNSL) Read more
A Phase 2 Study Of Paxalisib (GDC-0084) In Recurrent Or Refractory Primary Central Nervous System Lymphoma (PCNSL) Read more
An open-label phase II study to investigate the efficacy, safety, and pharmacokinetics of tirabrutinib in patients with Primary Central Nervous System Lymphoma (PCNSL) Read more
